Announcement
08.11.2011

The MermaiHD fase III study of Huntexil® (pridopidine) for the treatment of the
motor symptoms associated with Huntington's disease has been described in a
scientific article accepted by the well-reputed journal The Lancet Neurology.
The article will be published electronically today and later on in a printed
version entitled:

"Pridopidine for the treatment of motor function in patients with Huntington's
disease (MermaiHD):
a phase 3, randomised, double-blind, placebo-controlled trial"

The Lancet Neurology has found the article worthy of a separate press release
in which Dr Andrew Feigin, The Feinstein Institute for Medical Research, New
York, USA, is quoted as follows:
"A well tolerated drug that produces even small benefits for patients with
Huntington's disease would be a very welcome addition to the currently
available treatments for this debilitating disorder… Analysis of individual
items within the UHDRS-TMS in the MermaiHD study also suggests that pridopidine
might benefit features of HD for which there are currently no treatments (eye
movements, hand coordination, dystonia, and gait or balance problems)."

Please find a link to the article here, and a reprint of the article may be
requested via [email protected]

Patrik Dahlen, CEO of NeuroSearch, commented:
“We are very pleased with the academic recognition of the results obtained in
MermaiHD and now look even more forward to the initiation of Prime-HD being the
next Phase III study to bring us an important step forward in the process of
bringing Huntexil® to the market."

Patrik Dahlen
CEO

Contact person
Mads P.G. Korsgaard, PhD, Manager Investor Relations & Corporate Communications,
telephone: +45 4460 8309 or +45 4018 4997

About NeuroSearch
NeuroSearch is a European-based biopharmaceutical company listed on NASDAQ OMX
Copenhagen A/S (NEUR) and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is primarily to complete the development
and subsequently to market Huntexil® (pridopidine), a unique drug in clinical
Phase III for the treatment of the motor symptoms of Huntington's disease.
NeuroSearch also has a portfolio of other assets for outlicensing or
divestment. This includes tesofensine which has shown outstanding efficacy in
the treatment of obesity, the Integrative Screening Process (ISP), which is a
proprietary systems biology approach, as well as a broad range of ion channel
technologies and patented compounds identified as ion channel modulators.

Fonds.25-11 - MermaiHD study in Lancet Neurology - uk.pdf